Skip to main content
Equibles
PCRX logo

PCRX · Pacira BioSciences, Inc. · Earnings Call Transcripts & Audio

Track PCRX — free

Use PCRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PCRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$25.05 -0.60 (-2.34%) At close · Sep 30
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.00B
Shares
39.86M
Volume · Sep 30 628.47K Avg daily vol (3M) 576.36K

Pacira BioSciences, Inc. Earnings Call Transcripts

Quarterly earnings calls for Pacira BioSciences, Inc. (PCRX), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲31.1% $167.47M −$693,000 '22 Q3 22-11-14 ▲8% $171.96M −$10.10M '22 Q4 23-01-05 ▲1.5% $160.34M −$19.54M '23 Q1 23-05-03 ▲0% $169.47M $25.76M '23 Q2 23-08-02 ▼2.1% $163.93M $10.86M '23 Q3 23-11-02 ▲5.4% $181.24M $24.87M '23 Q4 24-02-29 ▲4.2% $167.12M $8.98M '24 Q1 24-05-07 ▲5% $178.02M $18.89M '24 Q2 24-07-30 ▲2.8% $168.57M −$143.47M '24 Q3 24-11-06 ▲3.3% $187.25M $16.04M '24 Q4 25-02-27 ▲1.1% $168.92M $4.81M '25 Q1 25-05-08 ▲1.7% $181.10M −$4.85M '25 Q2 25-08-05 ▲6.5% $179.52M $5.43M '25 Q3 25-11-06 ▲5.1% $196.87M $1.64M '25 Q4 26-02-26 ▲5% $177.38M $2.92M '26 Q1 26-04-30 LATEST ▲6.2% $192.40M $4.65M '26 Q2 26-08-04
Earnings call
FY26 · Q2
2026-08-04
Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript
Confident tone Pipeline catalysts and clinical readouts Exparel commercial performance and market access IOVERA divestiture and Zimmer Biomet partnership
Revenue
$192.40M
▲ 6.2% YoY
Diluted EPS
$0.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-08
Pacira BioSciences, Inc. (PCRX) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Pacira BioSciences, Inc. (PCRX) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-04-30
Pacira BioSciences, Inc. (PCRX) Q1 2026 Earnings Call Transcript
Confident tone Five by 30 strategy execution PCRX201 gene therapy pipeline EXPAREL commercial performance and growth
Revenue
$177.38M
▲ 5% YoY
Diluted EPS
$0.07
▼ 30% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-11
Pacira BioSciences, Inc. (PCRX) March 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-26
Pacira BioSciences, Inc. (PCRX) Q4 2025 Earnings Call Transcript
Confident tone 5x30 strategy and 2026 guidance Pipeline and clinical milestones Exparel (Expiril) commercial performance
Revenue
$196.87M*
▲ 5.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Pacira BioSciences, Inc. (PCRX) Q3 2025 Earnings Call Transcript
Confident tone 5x30 strategy Expiril commercial momentum GPO discounting and pricing pressure
Revenue
$179.52M
▲ 6.5% YoY
Diluted EPS
$0.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Pacira BioSciences, Inc. (PCRX) Q2 2025 Earnings Call Transcript
Confident tone EXPAREL commercial performance ZILRETTA and J&J partnership CMS reimbursement and policy
Revenue
$181.10M
▲ 1.7% YoY
Diluted EPS
$-0.11
▼ 128.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Pacira BioSciences, Inc. (PCRX) Q1 2025 Earnings Call Transcript
Positive tone EXPAREL Litigation Settlement and IP PCRX-201 Pipeline and HCAd Platform No Pain Reimbursement and EXPAREL Growth
Revenue
$168.92M
▲ 1.1% YoY
Diluted EPS
$0.10
▼ 47.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Pacira BioSciences, Inc. (PCRX) Q4 2024 Earnings Call Transcript
Confident tone iovera Reimbursement and SmartTip Launch 5/30 Strategy and Long-Term Growth Plan Gross Margin and Operating Expense Outlook
Revenue
$187.25M*
▲ 3.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Pacira BioSciences, Inc. (PCRX) Q3 2024 Earnings Call Transcript
Positive tone NOPAIN reimbursement and EXPAREL access iovera growth and reimbursement PCRX-201 gene therapy program
Revenue
$168.57M
▲ 2.8% YoY
Diluted EPS
$-3.11
▼ 1452.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-30
Pacira BioSciences, Inc. (PCRX) Q2 2024 Earnings Call Transcript
Confident tone EXPAREL lower extremity nerve block rollout NOPAIN Act reimbursement preparation EXPAREL patent litigation and generic threat
Revenue
$178.02M
▲ 5% YoY
Diluted EPS
$0.39
▼ 23.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Pacira BioSciences, Inc. (PCRX) Q1 2024 Earnings Call Transcript
Positive tone NOPAIN Reimbursement and Outpatient Opportunity ZILRETTA and iovera Performance PCRX-201 Gene Therapy Pipeline
Revenue
$167.12M
▲ 4.2% YoY
Diluted EPS
$0.19
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Pacira BioSciences, Inc. (PCRX) Q4 2023 Earnings Call Transcript
Positive tone EXPAREL financial performance NOPAIN Act and reimbursement EXPAREL lower extremity nerve block launch
Revenue
$181.24M*
▲ 5.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Pacira BioSciences, Inc. (PCRX) Q3 2023 Earnings Call Transcript
Revenue
$163.93M
▼ 2.1% YoY
Diluted EPS
$0.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Pacira BioSciences, Inc. (PCRX) Q2 2023 Earnings Call Transcript
Revenue
$169.47M
▲ 0% YoY
Diluted EPS
$0.51
▲ 27.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Pacira BioSciences, Inc. (PCRX) Q1 2023 Earnings Call Transcript
Revenue
$160.34M
▲ 1.5% YoY
Diluted EPS
$-0.43
▼ 386.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-05
Pacira BioSciences, Inc. (PCRX) Q4 2022 Earnings Call Transcript
Revenue
$171.96M*
▲ 8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Pacira BioSciences, Inc. (PCRX) Q3 2022 Earnings Call Transcript
Revenue
$167.47M
▲ 31.1% YoY
Diluted EPS
$-0.02
▼ 105.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-09-13
Pacira BioSciences, Inc. (PCRX) Q2 2022 Earnings Call Transcript
Revenue
$169.41M
▲ 24.9% YoY
Diluted EPS
$0.40
▼ 4.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-06-14
Pacira BioSciences, Inc. (PCRX) Q1 2022 Earnings Call Transcript
Revenue
$157.99M
▲ 32.7% YoY
Diluted EPS
$0.15
▼ 34.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-15
Pacira BioSciences, Inc. (PCRX) Q4 2021 Earnings Call Transcript
Revenue
$159.19M*
▲ 21.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-10-12
Pacira BioSciences, Inc. (PCRX) Q3 2021 Earnings Call Transcript
Revenue
$127.72M
▲ 8.7% YoY
Diluted EPS
$0.39
▼ 86.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Pacira BioSciences, Inc. (PCRX) Q2 2021 Earnings Call Transcript
Revenue
$135.59M
▲ 79.6% YoY
Diluted EPS
$0.42
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Pacira BioSciences, Inc. (PCRX) Q1 2021 Earnings Call Transcript
Revenue
$119.03M
▲ 12.6% YoY
Diluted EPS
$0.23
▲ 21.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-07
Pacira BioSciences, Inc. (PCRX) Q4 2020 Earnings Call Transcript
Revenue
$130.97M
▲ 7% YoY
Diluted EPS
$0.32
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-10-07
Pacira BioSciences, Inc. (PCRX) Q3 2020 Earnings Call Transcript
Revenue
$117.48M
▲ 12.2% YoY
Diluted EPS
$2.94
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Pacira BioSciences, Inc. (PCRX) Q2 2020 Earnings Call Transcript
Revenue
$75.50M
▼ 26.4% YoY
Diluted EPS
$-0.17
▼ 383.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Pacira BioSciences, Inc. (PCRX) Q1 2020 Earnings Call Transcript
Revenue
$105.68M
▲ 15.7% YoY
Diluted EPS
$0.19
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-20
Pacira BioSciences, Inc. (PCRX) Q4 2019 Earnings Call
Revenue
$122.42M
▲ 28.7% YoY
Diluted EPS
$-0.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–30 of 30 earnings calls
Key facts CIK 1396814 CUSIP 695127100 13F (30d) 8 filings 7 filers Visit website Investor relations